Recovery of cardiac function following COVID-19 - ECHOVID-19: a prospective longitudinal cohort study
Mats C H Lassen1, Kristoffer Grundtvig Skaarup1, Jannie N Lind1
1Department of Cardiology, Herlev & Gentofte Hospital, University of Copenhagen, Copenhagen, Denmark.
Insights
COVID-19 negatively impacted right ventricular (RV) function and cardiac biomarkers, which recovered post-infection. However, left ventricular (LV) function remained impaired after COVID-19, with both RV and LV function showing deficits compared to controls.
Area of Science:
- Cardiology
- Infectious Diseases
- Pulmonology
Background:
- Cardiovascular sequelae post-COVID-19 are not fully understood.
- Assessing cardiac function recovery after COVID-19 is crucial for patient management.
Purpose of the Study:
- To investigate the recovery of cardiac function following COVID-19 hospitalization.
- To compare cardiac function in recovered COVID-19 patients with matched controls.
Main Methods:
- Prospective longitudinal study of 91 hospitalized COVID-19 patients.
- Echocardiographic examinations during hospitalization and 2 months post-discharge.
- 1:1 matching with COVID-19-free controls by age and sex.
Main Results:
- Right ventricular (RV) function improved significantly post-COVID-19 (TAPSE, RVLS).
- Left ventricular (LV) global longitudinal strain (GLS) did not show significant improvement.
- Cardiac biomarkers (NT-proBNP) decreased, and troponins normalized post-COVID-19.
- Recovered patients exhibited impaired LV and RV function compared to controls.
Conclusions:
- Acute COVID-19 adversely affects RV function and cardiac biomarkers, with recovery observed.
- Reduced LV function during acute COVID-19 persists post-infection.
- Both LV and RV function remain impaired in recovered COVID-19 patients compared to controls.
Aims:
The degree of cardiovascular sequelae following COVID-19 remains unknown. The aim of this study was to investigate whether cardiac function recovers following COVID-19.
Methods And Results:
A consecutive sample of patients hospitalized with COVID-19 was prospectively included in this longitudinal study. All patients underwent an echocardiographic examination during hospitalization and 2 months later. All participants were successfully matched 1:1 with COVID-19-free controls by age and sex. A total of 91 patients were included (mean age 63 ± 12 years, 59% male). A median of 77 days (interquartile range: 72-92) passed between the two examinations. Right ventricular (RV) function improved following resolution of COVID-19: tricuspid annular plane systolic excursion (TAPSE) (2.28 ± 0.40 cm vs. 2.11 ± 0.38 cm, P < 0.001) and RV longitudinal strain (RVLS) (25.3 ± 5.5% vs. 19.9 ± 5.8%, P < 0.001). In contrast, left ventricular (LV) systolic function assessed by global longitudinal strain (GLS) did not significantly improve (17.4 ± 2.9% vs. 17.6 ± 3.3%, P = 0.6). N-terminal pro-B-type natriuretic peptide decreased between the two examinations [177.6 (80.3-408.0) ng/L vs. 11.7 (5.7-24.0) ng/L, P < 0.001]. None of the participants had elevated troponins at follow-up compared to 18 (27.7%) during hospitalization. Recovered COVID-19 patients had significantly lower GLS (17.4 ± 2.9% vs. 18.8 ± 2.9%, P < 0.001 and adjusted P = 0.004), TAPSE (2.28 ± 0.40 cm vs. 2.67 ± 0.44 cm, P < 0.001 and adjusted P < 0.001), and RVLS (25.3 ± 5.5% vs. 26.6 ± 5.8%, P = 0.50 and adjusted P < 0.001) compared to matched controls.
Conclusion:
Acute COVID-19 affected negatively RV function and cardiac biomarkers but recovered following resolution of COVID-19. In contrast, the observed reduced LV function during acute COVID-19 did not improve post-COVID-19. Compared to the matched controls, both LV and RV function remained impaired.
More Related Videos
Related Concept Videos
Acute Coronary Syndrome III: Diagnostic Studies
Cardiomyopathy VII: Pre and Post Operative Nursing Management
Cardiomyopathy V: Interprofessional Care
Cardiomyopathy IV: Restrictive Cardiomyopathy


